APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia A Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Hemophilia A Drug Industry Research Report 2026

Report ID 173997510522 December 2025131 pages

Choose your research edition.

Industry ResearchHemophilia A Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia A Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hemophilia A Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia A Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia A Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hemophilia A Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Hemophilia A Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Hemophilia A Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Hemophilia A Drug include Bayer AG, mAbxience SA, LFB SA, Immusoft Corp, Idogen AB, Green Cross Corp, Expression Therapeutics LLC, EpiVax Inc and Dimension Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Hemophilia A Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Hemophilia A Drug Market by Company

Bayer AG

mAbxience SA

LFB SA

Immusoft Corp

Idogen AB

Green Cross Corp

Expression Therapeutics LLC

EpiVax Inc

Dimension Therapeutics Inc

DBV Technologies SA

CSL Ltd

Chugai Pharmaceutical Co Ltd

Catalyst Biosciences Inc

Bioverativ Inc

BioMarin Pharmaceutical Inc

Hemophilia A Drug Segment by Type

ATXF-8117

BAY-1093884

BIVV-001

BS-027125

Concizumab

CSL-689

Others

Hemophilia A Drug Segment by Application

Clinic

Hospital

ASCs

Hemophilia A Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia A Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia A Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia A Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Hemophilia A Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Hemophilia A Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Hemophilia A Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Hemophilia A Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Hemophilia A Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Hemophilia A Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Hemophilia A Drug Revenue of Manufacturers (2021-2026) Table 9. Global Hemophilia A Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Hemophilia A Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Hemophilia A Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Hemophilia A Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Hemophilia A Drug, Product Type & Application Table 14. Global Hemophilia A Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Hemophilia A Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Bayer AG Company Information Table 19. Bayer AG Business Overview Table 20. Bayer AG Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Bayer AG Hemophilia A Drug Product Portfolio Table 22. Bayer AG Recent Developments Table 23. mAbxience SA Company Information Table 24. mAbxience SA Business Overview Table 25. mAbxience SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. mAbxience SA Hemophilia A Drug Product Portfolio Table 27. mAbxience SA Recent Developments Table 28. LFB SA Company Information Table 29. LFB SA Business Overview Table 30. LFB SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. LFB SA Hemophilia A Drug Product Portfolio Table 32. LFB SA Recent Developments Table 33. Immusoft Corp Company Information Table 34. Immusoft Corp Business Overview Table 35. Immusoft Corp Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Immusoft Corp Hemophilia A Drug Product Portfolio Table 37. Immusoft Corp Recent Developments Table 38. Idogen AB Company Information Table 39. Idogen AB Business Overview Table 40. Idogen AB Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Idogen AB Hemophilia A Drug Product Portfolio Table 42. Idogen AB Recent Developments Table 43. Green Cross Corp Company Information Table 44. Green Cross Corp Business Overview Table 45. Green Cross Corp Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Green Cross Corp Hemophilia A Drug Product Portfolio Table 47. Green Cross Corp Recent Developments Table 48. Expression Therapeutics LLC Company Information Table 49. Expression Therapeutics LLC Business Overview Table 50. Expression Therapeutics LLC Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Expression Therapeutics LLC Hemophilia A Drug Product Portfolio Table 52. Expression Therapeutics LLC Recent Developments Table 53. EpiVax Inc Company Information Table 54. EpiVax Inc Business Overview Table 55. EpiVax Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. EpiVax Inc Hemophilia A Drug Product Portfolio Table 57. EpiVax Inc Recent Developments Table 58. Dimension Therapeutics Inc Company Information Table 59. Dimension Therapeutics Inc Business Overview Table 60. Dimension Therapeutics Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio Table 62. Dimension Therapeutics Inc Recent Developments Table 63. DBV Technologies SA Company Information Table 64. DBV Technologies SA Business Overview Table 65. DBV Technologies SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. DBV Technologies SA Hemophilia A Drug Product Portfolio Table 67. DBV Technologies SA Recent Developments Table 68. CSL Ltd Company Information Table 69. CSL Ltd Business Overview Table 70. CSL Ltd Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. CSL Ltd Hemophilia A Drug Product Portfolio Table 72. CSL Ltd Recent Developments Table 73. Chugai Pharmaceutical Co Ltd Company Information Table 74. Chugai Pharmaceutical Co Ltd Business Overview Table 75. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio Table 77. Chugai Pharmaceutical Co Ltd Recent Developments Table 78. Catalyst Biosciences Inc Company Information Table 79. Catalyst Biosciences Inc Business Overview Table 80. Catalyst Biosciences Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio Table 82. Catalyst Biosciences Inc Recent Developments Table 83. Bioverativ Inc Company Information Table 84. Bioverativ Inc Business Overview Table 85. Bioverativ Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Bioverativ Inc Hemophilia A Drug Product Portfolio Table 87. Bioverativ Inc Recent Developments Table 88. BioMarin Pharmaceutical Inc Company Information Table 89. BioMarin Pharmaceutical Inc Business Overview Table 90. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio Table 92. BioMarin Pharmaceutical Inc Recent Developments Table 93. Global Hemophilia A Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Hemophilia A Drug Sales by Region (2021-2026) & (k units) Table 95. Global Hemophilia A Drug Sales Market Share by Region (2021-2026) Table 96. Global Hemophilia A Drug Sales by Region (2027-2032) & (k units) Table 97. Global Hemophilia A Drug Sales Market Share by Region (2027-2032) Table 98. Global Hemophilia A Drug Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Hemophilia A Drug Revenue Market Share by Region (2021-2026) Table 100. Global Hemophilia A Drug Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Hemophilia A Drug Revenue Market Share by Region (2027-2032) Table 102. North America Hemophilia A Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 104. North America Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 105. North America Hemophilia A Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Hemophilia A Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Hemophilia A Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 109. Europe Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 110. Europe Hemophilia A Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Hemophilia A Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Hemophilia A Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Hemophilia A Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Hemophilia A Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Hemophilia A Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 119. South America Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 120. South America Hemophilia A Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Hemophilia A Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Hemophilia A Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Hemophilia A Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Hemophilia A Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 128. Global Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 129. Global Hemophilia A Drug Sales Market Share by Type (2021-2026) Table 130. Global Hemophilia A Drug Sales Market Share by Type (2027-2032) Table 131. Global Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Hemophilia A Drug Revenue Market Share by Type (2021-2026) Table 134. Global Hemophilia A Drug Revenue Market Share by Type (2027-2032) Table 135. Global Hemophilia A Drug Price by Type (2021-2026) & (US$/unit) Table 136. Global Hemophilia A Drug Price by Type (2027-2032) & (US$/unit) Table 137. Global Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 138. Global Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 139. Global Hemophilia A Drug Sales Market Share by Application (2021-2026) Table 140. Global Hemophilia A Drug Sales Market Share by Application (2027-2032) Table 141. Global Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Hemophilia A Drug Revenue Market Share by Application (2021-2026) Table 144. Global Hemophilia A Drug Revenue Market Share by Application (2027-2032) Table 145. Global Hemophilia A Drug Price by Application (2021-2026) & (US$/unit) Table 146. Global Hemophilia A Drug Price by Application (2027-2032) & (US$/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Hemophilia A Drug Distributors List Table 150. Hemophilia A Drug Customers List Table 151. Hemophilia A Drug Industry Trends Table 152. Hemophilia A Drug Industry Drivers Table 153. Hemophilia A Drug Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Hemophilia A Drug Product Image Figure 5. Global Hemophilia A Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Hemophilia A Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Hemophilia A Drug Sales (2021-2032) & (k units) Figure 8. Global Hemophilia A Drug Average Price (US$/unit) & (2021-2032) Figure 9. ATXF-8117 Product Image Figure 10. BAY-1093884 Product Image Figure 11. BIVV-001 Product Image Figure 12. BS-027125 Product Image Figure 13. Concizumab Product Image Figure 14. CSL-689 Product Image Figure 15. Others Product Image Figure 16. Clinic Product Image Figure 17. Hospital Product Image Figure 18. ASCs Product Image Figure 19. Global Hemophilia A Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Hemophilia A Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Hemophilia A Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Hemophilia A Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Hemophilia A Drug Sales by Region in 2025 Figure 25. Global Hemophilia A Drug Revenue by Region in 2025 Figure 26. North America Hemophilia A Drug Market Size by Country in 2025 Figure 27. North America Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 28. North America Hemophilia A Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Hemophilia A Drug Market Size by Country in 2025 Figure 33. Europe Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Hemophilia A Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Hemophilia A Drug Market Size by Country in 2025 Figure 46. Asia Pacific Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Hemophilia A Drug Revenue Market Share by Country (2021-2032) Figure 48. China Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Hemophilia A Drug Market Size by Country in 2025 Figure 57. South America Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 58. South America Hemophilia A Drug Revenue Market Share by Country (2021-2032) Figure 59. Brazil Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Hemophilia A Drug Market Size by Country in 2025 Figure 63. Middle East and Africa Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Hemophilia A Drug Revenue Market Share by Country (2021-2032) Figure 65. Egypt Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Hemophilia A Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Hemophilia A Drug Sales Market Share by Type (2021-2032) Figure 71. Global Hemophilia A Drug Revenue Market Share by Type (2021-2032) Figure 72. Global Hemophilia A Drug Price (US$/unit) by Type (2021-2032) Figure 73. Global Hemophilia A Drug Sales Market Share by Application (2021-2032) Figure 74. Global Hemophilia A Drug Revenue Market Share by Application (2021-2032) Figure 75. Global Hemophilia A Drug Price (US$/unit) by Application (2021-2032) Figure 76. Hemophilia A Drug Value Chain Figure 77. Hemophilia A Drug Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Hemophilia A Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • ATXF-8117
  • BAY-1093884
  • BIVV-001
  • BS-027125
  • Concizumab
  • CSL-689
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
Companies covered
  • Bayer AG
  • mAbxience SA
  • LFB SA
  • Immusoft Corp
  • Idogen AB
  • Green Cross Corp
  • Expression Therapeutics LLC
  • EpiVax Inc
  • Dimension Therapeutics Inc
  • DBV Technologies SA
  • CSL Ltd
  • Chugai Pharmaceutical Co Ltd
  • Catalyst Biosciences Inc
  • Bioverativ Inc
  • BioMarin Pharmaceutical Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Hemophilia A Drug Market Size (2021-2032)
  4. 2.2.2 Global Hemophilia A Drug Sales (2021-2032)
  5. 2.2.3 Global Hemophilia A Drug Market Average Price (2021-2032)
  6. 2.3 Hemophilia A Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 ATXF-8117
  9. 2.3.3 BAY-1093884
  10. 2.3.4 BIVV-001
  11. 2.3.5 BS-027125
  12. 2.3.6 Concizumab
  13. 2.3.7 CSL-689
  14. 2.3.8 Others
  15. 2.4 Hemophilia A Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Clinic
  18. 2.4.3 Hospital
  19. 2.4.4 ASCs
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Hemophilia A Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Hemophilia A Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Hemophilia A Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Hemophilia A Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Hemophilia A Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Hemophilia A Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Hemophilia A Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Hemophilia A Drug, Established Date
  9. 3.9 Global Hemophilia A Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Bayer AG
  2. 4.1.1 Bayer AG Company Information
  3. 4.1.2 Bayer AG Business Overview
  4. 4.1.3 Bayer AG Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Bayer AG Hemophilia A Drug Product Portfolio
  6. 4.1.5 Bayer AG Recent Developments
  7. 4.2 mAbxience SA
  8. 4.2.1 mAbxience SA Company Information
  9. 4.2.2 mAbxience SA Business Overview
  10. 4.2.3 mAbxience SA Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 mAbxience SA Hemophilia A Drug Product Portfolio
  12. 4.2.5 mAbxience SA Recent Developments
  13. 4.3 LFB SA
  14. 4.3.1 LFB SA Company Information
  15. 4.3.2 LFB SA Business Overview
  16. 4.3.3 LFB SA Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 LFB SA Hemophilia A Drug Product Portfolio
  18. 4.3.5 LFB SA Recent Developments
  19. 4.4 Immusoft Corp
  20. 4.4.1 Immusoft Corp Company Information
  21. 4.4.2 Immusoft Corp Business Overview
  22. 4.4.3 Immusoft Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Immusoft Corp Hemophilia A Drug Product Portfolio
  24. 4.4.5 Immusoft Corp Recent Developments
  25. 4.5 Idogen AB
  26. 4.5.1 Idogen AB Company Information
  27. 4.5.2 Idogen AB Business Overview
  28. 4.5.3 Idogen AB Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Idogen AB Hemophilia A Drug Product Portfolio
  30. 4.5.5 Idogen AB Recent Developments
  31. 4.6 Green Cross Corp
  32. 4.6.1 Green Cross Corp Company Information
  33. 4.6.2 Green Cross Corp Business Overview
  34. 4.6.3 Green Cross Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Green Cross Corp Hemophilia A Drug Product Portfolio
  36. 4.6.5 Green Cross Corp Recent Developments
  37. 4.7 Expression Therapeutics LLC
  38. 4.7.1 Expression Therapeutics LLC Company Information
  39. 4.7.2 Expression Therapeutics LLC Business Overview
  40. 4.7.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio
  42. 4.7.5 Expression Therapeutics LLC Recent Developments
  43. 4.8 EpiVax Inc
  44. 4.8.1 EpiVax Inc Company Information
  45. 4.8.2 EpiVax Inc Business Overview
  46. 4.8.3 EpiVax Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 EpiVax Inc Hemophilia A Drug Product Portfolio
  48. 4.8.5 EpiVax Inc Recent Developments
  49. 4.9 Dimension Therapeutics Inc
  50. 4.9.1 Dimension Therapeutics Inc Company Information
  51. 4.9.2 Dimension Therapeutics Inc Business Overview
  52. 4.9.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio
  54. 4.9.5 Dimension Therapeutics Inc Recent Developments
  55. 4.10 DBV Technologies SA
  56. 4.10.1 DBV Technologies SA Company Information
  57. 4.10.2 DBV Technologies SA Business Overview
  58. 4.10.3 DBV Technologies SA Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 DBV Technologies SA Hemophilia A Drug Product Portfolio
  60. 4.10.5 DBV Technologies SA Recent Developments
  61. 4.11 CSL Ltd
  62. 4.11.1 CSL Ltd Company Information
  63. 4.11.2 CSL Ltd Business Overview
  64. 4.11.3 CSL Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 CSL Ltd Hemophilia A Drug Product Portfolio
  66. 4.11.5 CSL Ltd Recent Developments
  67. 4.12 Chugai Pharmaceutical Co Ltd
  68. 4.12.1 Chugai Pharmaceutical Co Ltd Company Information
  69. 4.12.2 Chugai Pharmaceutical Co Ltd Business Overview
  70. 4.12.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio
  72. 4.12.5 Chugai Pharmaceutical Co Ltd Recent Developments
  73. 4.13 Catalyst Biosciences Inc
  74. 4.13.1 Catalyst Biosciences Inc Company Information
  75. 4.13.2 Catalyst Biosciences Inc Business Overview
  76. 4.13.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio
  78. 4.13.5 Catalyst Biosciences Inc Recent Developments
  79. 4.14 Bioverativ Inc
  80. 4.14.1 Bioverativ Inc Company Information
  81. 4.14.2 Bioverativ Inc Business Overview
  82. 4.14.3 Bioverativ Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Bioverativ Inc Hemophilia A Drug Product Portfolio
  84. 4.14.5 Bioverativ Inc Recent Developments
  85. 4.15 BioMarin Pharmaceutical Inc
  86. 4.15.1 BioMarin Pharmaceutical Inc Company Information
  87. 4.15.2 BioMarin Pharmaceutical Inc Business Overview
  88. 4.15.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio
  90. 4.15.5 BioMarin Pharmaceutical Inc Recent Developments
5 Global Hemophilia A Drug Market Scenario by Region
  1. 5.1 Global Hemophilia A Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Hemophilia A Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Hemophilia A Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Hemophilia A Drug Sales by Region: 2027-2032
  5. 5.3 Global Hemophilia A Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Hemophilia A Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Hemophilia A Drug Revenue by Region: 2027-2032
  8. 5.4 North America Hemophilia A Drug Market Facts & Figures by Country
  9. 5.4.1 North America Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Hemophilia A Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Hemophilia A Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Hemophilia A Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Hemophilia A Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Hemophilia A Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Hemophilia A Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Hemophilia A Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Hemophilia A Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Hemophilia A Drug Market Facts & Figures by Country
  41. 5.7.1 South America Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Hemophilia A Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Hemophilia A Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Hemophilia A Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Hemophilia A Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Hemophilia A Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Hemophilia A Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Hemophilia A Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Hemophilia A Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Hemophilia A Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Hemophilia A Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Hemophilia A Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Hemophilia A Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Hemophilia A Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Hemophilia A Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Hemophilia A Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Hemophilia A Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Hemophilia A Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Hemophilia A Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Hemophilia A Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Hemophilia A Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Hemophilia A Drug Value Chain Analysis
  2. 8.1.1 Hemophilia A Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Hemophilia A Drug Production Mode & Process
  5. 8.2 Hemophilia A Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Hemophilia A Drug Distributors
  8. 8.2.3 Hemophilia A Drug Customers
9 Global Hemophilia A Drug Analyzing Market Dynamics
  1. 9.1 Hemophilia A Drug Industry Trends
  2. 9.2 Hemophilia A Drug Industry Drivers
  3. 9.3 Hemophilia A Drug Industry Opportunities and Challenges
  4. 9.4 Hemophilia A Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst